CCO Management Series
Adjuvant HER2-Positive Cancer: Integrating Prognostic Tools and Clinical Advances to Optimize Treatment
Current Clinical Data on Adjuvant Therapy for HER2-Positive Breast Cancer
|
Module 1 of 2
|
|
|
|
 Along with Nicholas J. Robert, MD, review the biology and testing of HER2, clinical studies evaluating HER2-based adjuvant regimens, side effects, and how to use such regimens in clinical practice. Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the significance of HER2 in breast cancer
- Recall current recommendations for establishing HER2 status
- Discuss results of adjuvant studies in HER2-positive breast cancer
- Describe the safety profile of HER2-targeting agents
|
Estimating Benefit and Prognosis With Adjuvant Therapy for HER2-Positive Breast Cancer
|
Module 2 of 2
|
|
|
|
Peter Ravdin, MD, PhD, discusses approaches to estimating the benefit of adjuvant therapy and determining the prognosis for patients with breast cancer. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss variables and biomarkers involved in determining the prognosis of patients with breast cancer
- Describe the effect of HER2 overexpresssion on the risk of breast cancer recurrence
- Explain the use of risk estimation programs in assessing the benefit of adjuvant therapies for breast cancer
- Describe the use of molecular assays as prognostic tools in the setting of breast cancer
|
Interactive Case
Treatment of a 32-Year-Old Patient With HER2-Positive Breast Cancer
 
- Daniel F. Hayes, MD
- Jeffrey B. Smerage, MD, PhD
|
|
|
 Join Daniel F. Hayes, MD, and Jeffrey B. Smerage, MD, PhD, as they discuss the adjuvant treatment of a pre-menopausal patient with HER2 positive breast cancer. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify appropriate adjuvant therapy for hormone receptor–negative, HER2-positive breast cancer
- Review current guidelines for the management of cardiotoxicity due to HER2-targeted breast cancer therapy
- Describe the options available for the treatment of metastatic HER2-positive breast cancer
|
Treatment of Breast Cancer in a 64-Year-Old Black Female With Multiple Positive Lymph Nodes
|
|
|
Along with Linda T. Vahdat, MD, investigate the treatment options available for a 64-year-old black woman with newly diagnosed invasive breast cancer Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss clinical trial updates of adjuvant treatment of HER2-positive breast cancer
- Explain the use of aromatase inhibitors vs tamoxifen in patients with hormone receptor–positive breast cancer
- Describe cardiotoxicity concerns in the treatment of breast cancer
|
CCO Slideset
Assessing Breast Cancer Prognosis and Applications for Clinical Practice
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 850 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|